Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: A case report

被引：9

作者：

Spirig C. ^{[1
]}

Omlin A. ^{[2
]}

D'Addario G. ^{[1
]}

Loske K.-D. ^{[3
]}

Esenwein P. ^{[4
]}

Geismar J.H. ^{[5
]}

Ruhstaller T. ^{[1
]}

机构：

[1] Department of Oncology-Hematology, Cantonal Hospital, St.Gallen

[2] Oncological Palliative Medicine, Cantonal Hospital, St.Gallen

[3] Department of Dermatology, Cantonal Hospital, St.Gallen

[4] Department of Plastic-Surgery, Cantonal Hospital, St.Gallen

[5] Department of Radiation Therapy, Cantonal Hospital, St.Gallen

来源：

Journal of Medical Case Reports | / 3卷 / 1期

关键词：

Pemetrexed; Musculus Latissimus Dorsi; Squamous Cell Lung Cancer; Radiation Recall; National Cancer Institute Common Toxicity Criterion;

D O I：

10.1186/1752-1947-3-93

中图分类号：

学科分类号：

摘要：

Introduction. Radiation recall dermatitis is a well known but still poorly understood inflammatory reaction. It can develop in previously irradiated areas and has been shown to be triggered by a variety of different drugs, including cytostatic agents. Pemetrexed may cause radiation recall dermatitis in pre-irradiated patients. Case presentation. We present the case of a 49-year-old Caucasian woman with non-small cell lung cancer who was initially treated with carboplatin and paclitaxel concomitant with radiotherapy after suffering a painful plexus brachialis infiltration. Due to disease progression, a second-line treatment with pemetrexed was started. A severe soft tissue necrosis developed despite steroid treatment and plastic surgery. Conclusion. To the best of our knowledge, we present the first case of a patient with severe soft tissue necrosis in a pre-irradiated area after pemetrexed therapy. We believe that physicians treating patients with pemetrexed should be aware of the severe, possibly life-threatening effects that may be induced by pemetrexed after previous radiation therapy. © 2009 Spirig et al; licensee BioMed Central Ltd.

引用

共 9 条

[1]

Burstein H.J., Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine, J Clin Oncol, 18, 3, pp. 693-694, (2000)

[2]

Raghavan V.T., Bloomer W.D., Merkel D.E., Taxol and radiation recall dermatitis, Lancet, 341, (1993)

[3]

Donaldson S.S., Glick J.M., Wilbur J.R., Adriamycin activating a recall phenomenon after radiation therapy, Ann Intern Med, 81, 3, pp. 407-408, (1974)

[4]

Barlesi F., Tummino C., Tasei A.M., Astoul P., Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis, Lung Cancer, 54, 3, pp. 423-425, (2006)

[5]

Hureaux J., Le Guen Y., Tuchais C., Savary L., Urban T., Radiation recall dermatitis with pemetrexed, Lung Cancer, 50, 2, pp. 255-258, (2005)

[6]

Jeter M.D., Janne P.A., Brooks S., Burstein H.J., Wen P., Fuchs C.S., Luettler J.S., Devlin P.M., Salgia I.Z., Gemcitabine-induced radiation recall, Int J Radiat Oncol Biol Phys, 53, 2, pp. 394-400, (2002)

[7]

Schweitzer V.G., Juillard G.J., Bajada C.L., Parker R.G., Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel, Cancer, 76, 6, pp. 1069-1072, (1999)

[8]

Saif M.W., Sellers S., Russo S., Gemcitabine-related radiation recall in a patient with pancreatic cancer, Anticancer Drugs, 17, 1, pp. 107-111, (2006)

[9]

D'Angio G.J., Farber S., Maddock C.L., Potentiation of x-ray effects by actinomycin D, Radiology, 73, pp. 175-177, (1959)

← 1 →